11/14/2024 3:53 PM | Fulcrum Therapeutics (Subject) Nantahala Capital Management, LLC (Filed by)
| Form SCHEDULE 13G | |
11/14/2024 3:25 PM | Fulcrum Therapeutics (Subject) SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
| Form SC 13G/A | |
11/14/2024 5:15 AM | Fulcrum Therapeutics (Subject) RTW INVESTMENTS, LP (Filed by)
| Form SC 13G/A | |
11/13/2024 6:05 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/13/2024 6:10 AM | Fulcrum Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
11/12/2024 2:51 PM | Fulcrum Therapeutics (Subject) VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/04/2024 10:49 AM | Fulcrum Therapeutics (Subject) VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
|
10/07/2024 10:37 AM | FMR LLC (Filed by) Fulcrum Therapeutics (Subject)
| Form SC 13G/A | |
09/24/2024 3:05 PM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/23/2024 3:15 PM | Fulcrum Therapeutics (Issuer) Kolchinsky Peter (Reporting) RA Capital Healthcare Fund LP (Reporting) RA CAPITAL MANAGEMENT, L.P. (Reporting) Shah Rajeev M. (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
09/20/2024 3:21 PM | Fulcrum Therapeutics (Subject) TCG Crossover GP II, LLC (Filed by)
| Form SC 13G | |
09/16/2024 7:21 PM | Fulcrum Therapeutics (Subject) RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
09/12/2024 11:43 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/23/2024 3:16 PM | Fulcrum Therapeutics (Subject) RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
08/22/2024 3:02 PM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/31/2024 6:55 AM | Fulcrum Therapeutics (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
07/31/2024 6:10 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/31/2024 6:15 AM | Fulcrum Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
07/08/2024 7:00 AM | Fulcrum Therapeutics (Issuer) Sapir Alex (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/17/2024 3:37 PM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/13/2024 6:15 AM | Fulcrum Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/13/2024 6:05 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/09/2024 3:10 PM | Fulcrum Therapeutics (Issuer) Tourangeau Greg (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/25/2024 11:15 PM | Fulcrum Therapeutics (Filer)
| Form EFFECT | |
03/20/2024 3:10 PM | Fulcrum Therapeutics (Issuer) Horn Patrick Taylor (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
03/20/2024 3:15 PM | Fulcrum Therapeutics (Issuer) Horn Patrick Taylor (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/08/2024 5:00 PM | Fulcrum Therapeutics (Subject) Tourangeau Greg (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/08/2024 5:05 PM | Fulcrum Therapeutics (Issuer) Tourangeau Greg (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/27/2024 6:01 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/14/2024 6:53 AM | Fulcrum Therapeutics (Subject) RTW INVESTMENTS, LP (Filed by)
| Form SC 13G/A | |
02/13/2024 11:08 AM | Fulcrum Therapeutics (Subject) SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
| Form SC 13G/A | |
02/07/2024 6:44 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by) Fulcrum Therapeutics (Subject)
| Form SC 13G/A | |
01/30/2024 8:00 PM | Fulcrum Therapeutics (Issuer) Oltmans Curtis Gale (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/30/2024 8:05 PM | Fulcrum Therapeutics (Issuer) Musso Alan A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/30/2024 8:10 PM | Fulcrum Therapeutics (Issuer) Tourangeau Greg (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |